Overview
Elad Walach is a co-founder and chief executive officer of Aidoc, a Tel Aviv-based clinical artificial intelligence company founded in early 2016. Aidoc’s leadership biography describes Walach as an expert in AI with visionary business insights in the healthcare space. Aidoc embeds AI into radiology and acute care workflows, supporting clinical decision-making across a large global hospital install base.
Aidoc’s platform has analyzed more than one hundred twenty million patient cases per company announcements reviewed in 2026, extending from triage alerts into generative report drafting workflows such as First Read for chest radiographs.
Role and company
As co-founder and CEO, Walach has led Aidoc through four investment rounds bringing total investment to $250 million, drove commercial availability of 20 product lines, created an install base of over 1,600 global hospitals, and grew the company to over 450 employees per his official leadership biography.
Aidoc’s product portfolio spans care coordination, triage, and generative AI modules built on its clinically validated CARE foundation model — positioning the company as infrastructure radiology departments integrate rather than a single-algorithm point solution.
Background and career context
Aidoc’s leadership page establishes Walach as co-founder and CEO since early 2016 without detailing prior employers on the cited biography. His public identity is tied to scaling clinical AI inside hospital operations — a harder commercial problem than consumer AI because deployment requires PACS integration, radiologist workflow adoption, and regulatory clearance pathways.
Walach’s quoted emphasis in company news on moving from triage alerts to report drafting reflects Aidoc’s 2026 product strategy: expand AI from detection into documentation workflows where clinician oversight and liability carry greater weight.
Company-building or leadership context
Walach co-founded Aidoc in Tel Aviv in 2016 and has remained CEO through multiple funding rounds and product line expansion to 20 commercial offerings. Aidoc’s growth model combines direct hospital sales with embedded workflow AI that radiologists encounter inside existing reading environments.
The leadership biography’s quantified milestones — 1,600 hospitals, 450 employees, $250M investment — give procurement committees concrete scale indicators when evaluating imaging AI vendors against smaller regional startups.
Public milestones
Aidoc received FDA Breakthrough Device Designation for First Read — AI designed to analyze chest radiographs and generate preliminary radiology report text — announced June 25, 2026. The company previously received Breakthrough designation for CARE Triage in September 2025 per Aidoc news timeline. Aidoc announced $150M Series E financing in April 2026 per company press materials.
Walach remains the CEO named on Aidoc’s leadership biography through these regulatory and financing milestones.
Why their work matters
Aidoc under Walach demonstrates that clinical imaging AI can achieve thousand-hospital deployment scale when products integrate into existing radiology workflows rather than requiring separate viewing environments. The move from triage to generative report drafting tests whether hospital buyers trust AI-generated text in medicolegal contexts — a frontier beyond alert-based CAD tools.
For Brel’s healthcare AI coverage, Walach’s Aidoc is the benchmark for acute-care imaging AI commercialization depth, distinct from outpatient ambient documentation or revenue-cycle GenAI vendors.
Sources and references
Primary sourcing: Aidoc Elad Walach leadership biography and Aidoc About page, reviewed July 10, 2026.
- Aidoc — Elad Walach (aidoc.com)
- Aidoc — About (aidoc.com)
Breakthrough designation and financing milestones from Aidoc newsroom releases cross-referenced on company site. No prior employment claims beyond leadership biography.